Savvy Wealth
Savvy Wealth gives independent financial advisors an operating platform that combines practice tools, investment support and AI-assisted client work.
$100MSeries C
ParticipantEC
Euclidean Capital
Activity from announced rounds
Activity in this selectionUnited States · Oct 9, 2026 · Sep 10, 2026
Euclidean Capital is the investor identified in Circle Pharma’s issuer announcement and by transaction counsel for InduPro.
Recorded funding activity
Circle Pharma develops macrocycle medicines using computational and structure-based methods. The recorded history also includes Savvy Wealth’s operating tools and investment support for financial advisors. Multiple Savvy entries remain separate events pending their own event-level review.
- Rounds participated in
- 2
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 1 First participation on record · 1 follow-on
- Funding in participating rounds
- $192.5M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionCircle Pharma, Inc.
Circle Pharma discovers macrocycle medicines for cancer and other serious diseases using its MXMO platform, which combines computational, structure-based design with synthetic chemistry to create cell-permeable compounds against difficult protein targets. Its lead programs are investigational and at discovery or preclinical stages.
$92.5MSeries E
Participant